Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 5 m8 G' e! m# p# Z2 v1 x' K1 m
5 b1 o. Z" E: C D) s, _% |6 L# z# Y6 U7 n' d* ]9 I1 X# ?- g
Sub-category:/ n! B7 G4 H8 y; S" t+ A
Molecular Targets 9 Y1 p f4 i Q' ?" U8 N8 g
; G5 _5 m6 O' F$ R( I0 L+ e4 J# ~! s
Category:; Q* r* {4 a# P2 y/ S
Tumor Biology - L! o" Z% d+ D8 h
7 L6 x Y1 e# F+ I' p4 ~) q9 n
4 a! Y; }. N" e" B" KMeeting:
# y0 t) `* g f2 M8 y3 t' e8 |2011 ASCO Annual Meeting 8 e. a* }: z1 y& O/ T, ~4 ?
! w6 u* q8 _. I6 d4 t6 ]( m2 k2 @8 [. o1 T* G! ^
Session Type and Session Title:; y+ @2 {2 J4 {9 t2 K9 }
Poster Discussion Session, Tumor Biology " F) Z1 [. C9 e; H4 ?
' A1 P; e! Y# }3 Y
& N: G9 s' X1 W" u" C; JAbstract No:
3 V) A& A/ a; [! n7 a# c8 i10517
) {0 C! F% v( U6 h5 }- ^* @7 [6 B/ d- V7 w/ u( C
) z% @: p( P. T7 ]: j! o$ QCitation:8 g8 o/ K4 ^$ ^0 x! }
J Clin Oncol 29: 2011 (suppl; abstr 10517)
$ o0 Z. h- C0 I' N
1 J9 h5 {7 A% W; C' Y6 U& M
) {) v+ m1 H2 z' ^ k& eAuthor(s):
& X/ l( _' S3 P8 sJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
5 }2 ~$ R# {. p1 E( f9 b: [, G" |' ~0 r% B% S# ?
?1 |% C) s7 z' D# C' o
$ f$ S; g" y* g6 FAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
7 T- j: ] Y8 K. H6 u" m% H) C* C0 d1 n/ x7 ~7 ]# c, _# b8 ]
Abstract Disclosures5 K7 d; N3 V; n8 E* R
" N# M, d/ g) }+ |( Y- _; ~
Abstract:5 W) m9 P0 }7 g
' ]$ u1 g8 `5 ], X o: E3 n
5 E) B, ~- Q: C0 k+ E6 B0 B! F6 _! nBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.% O3 ` k' ]7 ^
+ {. `' E1 H! {* m0 ]* n 2 O+ Q) N' E ~4 g2 t5 Y% k
|